Commentary|Videos|July 7, 2026

Updated AUA/SUO Advanced Prostate Cancer guideline emphasizes role of PSMA-PET

Fact checked by: Hannah Clarke, Tracy Ann Politowicz

Kristen Scarpato, MD, discusses 2026 AUA/SUO Advanced Prostate Cancer Guideline amendment recommendations on the use of PSMA-PET imaging for staging and treatment selection.

In this interview, Kristen R. Scarpato, MD, MPH, discusses 2026 American Urological Association (AUA)/Society of Urologic Oncology (SUO) Advanced Prostate Cancer Guideline amendment recommendations regarding the role of prostate-specific membrane antigen (PSMA)-PET imaging across the prostate cancer continuum, highlighting its impact on disease detection, treatment decision-making, and ongoing questions surrounding its clinical implications.¹ Scarpato is an associate professor of urology at Vanderbilt University Medical Center in Nashville, Tennessee.

Related to this article

November 13th, 2026

Treatment interruptions in prostate cancer: Balancing PSA kinetics and quality of life

Aaron Berger, MD, discusses testosterone recovery after prostate cancer therapy interruption and its implications for quality of life, PSA kinetics, and treatment decisions.

November 6th, 2026

Treatment intensification in mHSPC: Balancing disease burden, biomarkers, and toxicity

Benjamin Garmezy, MD, discusses personalizing mHSPC treatment intensification based on disease burden, molecular biomarkers, and patient-specific factors.

November 4th, 2026

Alicia Morgans, MD, discusses cognitive outcomes with darolutamide vs enzalutamide

Alicia Morgans, MD, discusses ARACOG findings on cognitive outcomes with darolutamide vs enzalutamide and the influence of genetic dementia risk.

November 3rd, 2026

Aaron Berger, MD, discusses considerations for ARPI treatment breaks

Aaron Berger, MD, discusses patient selection for ARPI treatment holidays, monitoring during interruptions, and the role of testosterone recovery in interpreting PSA kinetics.